Atlas Trials

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Clinical trial NCT01455051 · COMPLETED

Trial details

NCT number
NCT01455051
Sponsor
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia
Start date
2011-10-01
Primary completion
2014-10-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.